A Randomised, Double-Blind, Parallel-Group Study to Compare the Efficacy and Safety of Ondansetron (GR38032F) plus Dexamethasone with Metoclopramide plus Dexamethasone in the Prophylaxis of Nausea and Emesis Induced by Carboplatin Chemotherapy

Oncology (Switzerland)

Volumn 54, Issue 1, 1997, Pages 7-14

  du Bois, A ^a   McKenna, C J ^b   Andersson, H ^c   Lahousen, M ^d   Kitchener, H ^e   Pinter, T ^f   Capstick, V ^g   Wilkinson, J R ^g  

^a Klin F Anaesthesie Oper I   (Germany)

^b GLAXOSMITHKLINE   (United Kingdom)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d University Klinik   (Austria)

^e ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^f Department of Obstetrics and Gynecology   (Hungary)

^g CROSS CANCER INSTITUTE   (Canada)

Author keywords

Carboplatin chemotherapy; Emesis; Ondansetron; Supportive care

Indexed keywords

ANTIEMETIC AGENT; CARBOPLATIN; DEXAMETHASONE; METOCLOPRAMIDE; ONDANSETRON;

ADULT; AGED; ANXIETY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYNDROME; FATIGUE; FEMALE; FLUSHING; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; INVOLUNTARY MOVEMENT; MAJOR CLINICAL STUDY; MALAISE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; OVARY CANCER; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; VOMITING;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CARBOPLATIN; DEXAMETHASONE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; METOCLOPRAMIDE; MIDDLE AGED; NAUSEA; ONDANSETRON; OVARIAN NEOPLASMS; TREATMENT OUTCOME; VOMITING;

EID: 0031060358     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227652     Document Type: Article

References (15)

1. Office of Population Censuses and Surveys: Mortality statistics 1992; series DH2:19.
2. Cancer Facts and Figures, rev vers, New York, American Cancer Society, 1995.
3. Martin M, Diaz-Rubio E, Sanchez J, Almena-rez J, Lopez-Vcga JM: The natural course of emesis after carboplatin treatment, Acta Oncol 1990;29:593-595.
4. Smith DB, Rustin GJS, Howells N, McQuade BA, for the North Thames Ovary Group: Ondansetron (GR38032F): Effective anti-emetic prophylaxis for patients receiving carboplatin chemotherapy, Br J Cancer 1990:62:524.
5. Gridelli C, Incoronato P, Airoma G, Pepe R, Arpinclli F, Bianco AR: Ondansetron in the prophylaxis of nausea and vomiting induced by carboplatin combination chemotherapy, Eur J Cancer 1993;29A, 651.
6. Smith DB, Rustin GJS, Howells N, Lambert HE, McQuade B, for the North Thames Ovary Group: A phase 2 study of ondansetron as antiemetic prophylaxis in patients receiving carboplatin for advanced ovarian cancer, Ann Oncol 1991;2:607-608.
7. Harvey VJ, Evans BD, Mitchell PLR, Mak D, Neave LM, Langley GB, Dickson DSP: Reduction of carboplatin induced emesis by ondansetron, Br J Cancer 1991;63:942-944.
8. Roila F, Tonat M, Cognetti F, Cortesi E, Favelli G, Marangolo M, ct al: Prevention of cispla-tin-induced emesis: A double-blind, multi-centre, randomised, cross-over study, comparing ondansetron and ondansetron plus dexa-methasone, J Clin Oncol 1991;4:675-678.
9. Campora E, Giudicci S, Mcrlini L, Robagotti A, Rosso R: Ondansetron and dcxamethasone versus standard combination anti-emetic therapy, Am J Clin Oncol 1994;17:552-562.
10. Koch GG, Edwards S: Clinical efficacy trials with categorical data: in Pearce ICE (ed): Bio-pharmaceutical statistics for drug development, New York, Dekker, 1988, vol 9, pp 403-457.
11. du Bois A, Vach W, Cramer-Giraud U, Thomssen C, Glaubitz M, Fiola M, for the German Ondansetron study group: Pattern of car-boplatin-induced emesis, Anti-Cancer Drugs 1995;6:1-7.
12. du Bois A, Vach W, Thomssen C, Karck U, Madjar H, Prompeler H, Meerpohl HG: Comparison of the emetogenic potential between cisplatin and carboplatin in combination with alkylating agents, Acta Oncol 1994:33:531-535.
13. du Bois A, Meerpohl HG, Siebert C, Bcrek JS, Pfleidercr A: Excretion patterns of 5-H1AA under platinum-based chemotherapy: The role of 5-HT in drug-induced emesis, Proc ASCO 1992:381.
14. Schmoll HJ: The role of ondansetron in the treatment of emesis induced by non-cisplatin containing regimens, Eur J Cancer Clin Oncol 1989;25(suppl):535-539.
15. Soukop M, McQuade B, Hunter E, et al; Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer, Oncology 1992;49:295-304.